Sugi Predict

Sugi Predict / Compounds / SCHEMBL158153

SCHEMBL158153

SCHEMBL158153

COc1cc(F)c(N)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 1/20 0.56
▸ ALDH1A1 P00352 5/20 0.50
▸ CYP1A1 P04798 2/20 0.41
▸ CYP1B1 Q16678 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP3A4 P08684 4/20 0.39
▸ PKM P14618 3/20 0.39
▸ NQO2 P16083 2/20 0.38
▸ CYP19A1 P11511 2/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NOS3 P29474 1/20 0.37
▸ NOS1 P29475 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30184066 0.88 TAAR1 (0.50) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL21000886 0.88 TAAR1 (0.50) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL18713980 0.86 TAAR1 (0.48) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL13862076 0.86 TAAR1 (0.48) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL1337757 0.81 KDM1A (0.40) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL9219925 0.78 TAAR1 (0.50) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2
SCHEMBL20670508 0.78 ALDH1A1 (0.43) TAAR1ALDH1A1MAPK1CYP3A4MAPT
SCHEMBL29664110 0.78 ALDH1A1 (0.43) TAAR1ALDH1A1MAPK1CYP3A4MAPT
SCHEMBL7248019 0.78 KDM4E (0.46) TAAR1ALDH1A1TDP1MAPK1PKM
SCHEMBL1337769 0.78 KDM1A (0.39) TAAR1ALDH1A1CYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
EP-4225435-B1 AMINOIMIDAZOLE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2024-12-11 — — EP disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
EP-3532474-B1 4,5-ANNULATED 1,2,4-TRIAZOLONES BAYER AG (DE) 2024-03-27 — — EP disclosed
CN-114921391-B 4, 5-cyclic 1,2, 4-triazolones 拜耳股份有限公司 2024-01-02 — — CN disclosed
US-20230373930-A1 AMINOIMIDAZOLE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-11-23 — — US disclosed
WO-2010048131-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 — — WO disclosed
EP-2144902-A1 [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-01-20 — — EP disclosed
WO-2009137651-A2 FUNGICIDAL SUBSTITUTED AZOLES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-11-12 — — WO disclosed
WO-2009137538-A2 FUNGICIDAL SUBSTITUTED AZOLES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-11-12 — — WO disclosed
WO-2009045992-A2 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-09 — — WO disclosed
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2008-11-27 — — US disclosed
WO-2008137435-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-13 — — WO disclosed
US-20060046999-A1 Monocyclic aroylpyridinones as antiinflammatory agents BAYER HEALTHCARE AG (DE) 2006-03-02 — — US disclosed
EP-1487794-A1 MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS Bayer Aktiengesellschaft (DE) 2004-12-22 — — EP disclosed
WO-2003076405-A1 MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS BAYER HEALTHCARE AG (DE) 2003-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046999-A1 Monocyclic aroylpyridinones as antiinflammatory agents PTGIS, PTGES, PTGES2 TAAR1 1104/4885ALDH1A1 413/4885CYP1A1 193/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 TAAR1 1634/4885ALDH1A1 2427/4885CYP1A1 776/4885
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR6, GPR139 TAAR1 156/4885ALDH1A1 2019/4885CYP1A1 716/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR TAAR1 1564/4885ALDH1A1 2642/4885CYP1A1 801/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TAAR1 1634/4885ALDH1A1 2427/4885CYP1A1 776/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TAAR1 1634/4885ALDH1A1 2427/4885CYP1A1 776/4885
US-20230373930-A1 AMINOIMIDAZOLE FPR2 AGONISTS FPR2, FPR1, FPR3 TAAR1 372/4885ALDH1A1 3618/4885CYP1A1 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.